Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Advanced Endometrial Cancer: Treatment Optimization : Episode 12

      Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

      January 6, 2023
      By Courtney R. Arn, APRN-CNP
      Kimberly Halla, NP
      • Kathleen Lutz, RN, NP-BC WH
      • Kimberly A. Spickes, CNP

      Commentary
      Video

      The panel explains how to educate patients on the adverse effects they may experience with chemotherapy, their options for management, and the importance of encouraging patients to contact their care team.

      EP: 1.Symptoms and Diagnosis of Endometrial Cancer

      EP: 2.Initial Consultation of Patients With Advanced Endometrial Cancer

      EP: 3.Conversations with Patients With Advanced Endometrial Cancer Before and After Diagnosis

      EP: 4.Resources for Patients With Endometrial Cancer

      EP: 5.Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer

      EP: 6.Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer

      EP: 7.Currently Available Treatment Modalities in Endometrial Cancer

      EP: 8.First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery

      EP: 9.Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

      EP: 10.Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

      EP: 11.Treatment Options for Patients with Recurrent Endometrial Cancer

      Now Viewing

      EP: 12.Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

      EP: 13.Monitoring Patients on Therapy for Recurrent Endometrial Cancer

      EP: 14.Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

      EP: 15.Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

      EP: 16.Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

      EP: 17.Greatest Unmet Needs for Patients with Endometrial Cancer

      EP: 18.Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a man in a suit smiling in front of an Oncology Nursing News background
      Gynecologic Cancers
      Related Content

      Graphic of endometrial cancer cells

      Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer

      Jax DiEugenio
      June 27th 2025
      Article

      In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.


      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      June 15th 2023
      Podcast

      Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.


      Image of icons representing different organs in a circle with the female reproductive system in the middle under a magnifying glass

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Chris Ryan
      June 23rd 2025
      Article

      The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Photo of a person holding their abdomen in discomfort

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      Roman Fabbricatore
      June 9th 2025
      Article

      Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

      Related Content

      Graphic of endometrial cancer cells

      Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer

      Jax DiEugenio
      June 27th 2025
      Article

      In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.


      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      June 15th 2023
      Podcast

      Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.


      Image of icons representing different organs in a circle with the female reproductive system in the middle under a magnifying glass

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Chris Ryan
      June 23rd 2025
      Article

      The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Photo of a person holding their abdomen in discomfort

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      Roman Fabbricatore
      June 9th 2025
      Article

      Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

      Latest Conference Coverage

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.